课题基金 / 基金详情

项目摘要

项目成果

Robert G. Whalen的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):临床试验表明,HIV-1感染不能通过天然存在的病毒包膜(Env)蛋白免疫来预防。然而,很明显Env含有可以诱导广泛中和抗体的表位。现在的努力集中在修饰HIV-1 Env以提高其诱导中和抗体的能力的方法上。 HIV-1 Env是一种跨膜糖蛋白。gp 41的膜近端外部区域含有似乎与膜脂质相互作用的中和表位。这些表位是从感染患者中分离的三种单克隆抗体(称为2F 5,4 E10和Z13)的靶标。 这些抗体对HIV-1具有广泛的交叉中和活性,并且似乎通过与肽表位和膜脂质的相互作用而起作用。因此,在设计HIV-1疫苗的免疫原时考虑这些膜相互作用是很重要的。解决这个问题的一种实验方法是将表位定位在病毒样脂蛋白颗粒(VLP)的膜附近。 基于描述使用肝炎B表面抗原(HBsAg)作为VLP和免疫原的文献,我们假设它将作为HIV-1 Env蛋白近膜外部区域中发现的广泛中和表位的合适载体分子。 在这个I期SBIR提案中,我们建议创建与HBsAg VLP部分融合的HIV衍生表位序列的几种变体,以便可以鉴定最有效的免疫原。评估蛋白质免疫原性的唯一方法是免疫接种,最初在小动物模型中进行,然后进行临床试验。 目前第一阶段建议的具体目标如下。 - 具体目标#1:将HIV-1 Env gp 41表位插入HBsAg。 - 具体目标#2:评价嵌合HIV-HBsAg颗粒的分泌和抗原性。 - 具体目的#3:评价嵌合HIV-HBsAg颗粒的免疫原性。
英文摘要
DESCRIPTION (provided by applicant): Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with naturally occurring viral envelope (Env) proteins. However, it is clear that Env contains epitopes that can induce broadly neutralizing antibodies. Efforts are now focused on ways to modify the HIV-1 Env to improve its ability to induce neutralizing antibodies. The HIV-1 Env is a transmembrane glycoprotein. The membrane-proximal external region of gp41 contains neutralizing epitopes that appear to interact with membrane lipids. These epitopes are the target of three monoclonal antibodies (called 2F5, 4E10, and Z13) that have been isolated from infected patients. These antibodies possess broad cross-neutralization activity against HIV-1 and appear to function by interaction with the peptide epitope and membrane lipids. It is therefore important to consider these membrane interactions in the design of immunogens for vaccines to HIV-1. One experimental approach to this problem is to position the epitopes in proximity to the membrane of a virus-like lipoprotein particle (VLP). Based on the literature describing the use of the hepatitis B surface antigen (HBsAg) as a VLP and immunogen, we hypothesize that it will serve as a suitable carrier molecule for the broadly neutralizing epitopes found in the membrane-proximal external region of the HIV-1 Env protein. In this Phase I SBIR proposal, we propose to create several variants of the HIV-derived epitope sequences fused to the HBsAg VLP moiety so that the most effective immunogens can be identified. The only way to evaluate the immunogenicity of a protein is by immunization, carried out initially in small animal models followed by clinical trials. The Specific Aims of the present Phase I proposal are as follows. - Specific Aim #1: Insert HIV-1 Env gp41 epitopes into the HBsAg. - Specific Aim #2: Evaluate secretion and antigenicity of chimeric HIV-HBsAg particles. - Specific Aim #3: Evaluate immunogenicity of chimeric HIV-HBsAg particles.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutic Vaccines for Chronic HBV
  • 批准号:
    8394626
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Novel Tetravalent Vaccines for Dengue Virus
  • 批准号:
    8315393
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
  • 批准号:
    8329484
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
  • 批准号:
    8410439
  • 项目类别:
  • 资助金额:
    $59.78万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
海外基金